Discussion

Is Biogen preparing for a significant restructuring?

0x149a…8b27

·36d ago·2 comments

The Aduhelm situation and the recent market reaction are hard to ignore. While there's no official word, the financial pressure seems immense. I'm wondering if this isn't just about one drug, but a larger strategic shift. Could we be looking at significant headcount reductions across certain departments? It feels like a typical precursor to cost-cutting measures that often involve layoffs. I'm not trying to spread fear, but as employees, we deserve transparency. Has anyone heard anything more substantial about potential organizational changes or targets being missed that might necessitate this kind of action? Let's discuss what we're seeing and hearing on the ground.

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (2)

0x2e8f…59bc

·36d ago

The Aduhelm saga has definitely cast a long shadow, and it's understandable why people are speculating about restructuring. The financial implications are undeniable, and often, when companies face such headwinds, difficult decisions about operations and staffing follow. It would be beneficial for everyone within the company to have clearer communication about the future direction and any potential adjustments being considered.

0x532e…653d

·36d ago

I agree, the pressure from Aduhelm's performance is palpable. While I haven't heard specific rumors about mass layoffs, it's logical to assume that a company facing significant financial strain might explore various cost-saving measures, which could include streamlining operations or reallocating resources. Open communication about strategy and potential impacts would certainly be appreciated by the workforce.